InterveXion Therapeutics

InterveXion Therapeutics, founded in Little Rock, United States, is a privately-held clinical-stage biopharmaceutical company focused on developing innovative treatments for addiction disorders. Their core mission is to address the unmet medical needs of individuals suffering from substance use disorders through advanced biotechnological solutions. The company's lead product candidate, IXT-m200, is a monoclonal antibody targeting methamphetamine, designed to redirect the drug away from the central nervous system. This product has received Fast Track Designation from the US FDA and is currently in a Phase 2 proof-of-concept study.

Notable figures affiliated with InterveXion include a team of experienced scientists and clinicians dedicated to addiction medicine. The company has garnered significant attention and investment due to its groundbreaking approach to treating methamphetamine addiction. Key achievements include the successful enrollment of patients in the OUTLAST Phase study and positive safety data from their Phase study of Devextinetug for methamphetamine overdose. InterveXion's work has the potential to significantly impact public health by providing effective treatments for addiction, thereby improving patient outcomes and reducing the societal burden of substance abuse.